To Assess the Effect of Administration of 2 Formulation of AZD3241 on Blood Concentration in Healthy Volunteers
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the pharmacokinetics of AZD3241 following multiple administration of 2 new,
different extended release formulations of tablets of AZD3241 (300 mg), in relation to the
100 mg extended release tablet used in a previous study and potential food interaction. The
safety and tolerability of AZD 3241 will also be investigated as a secondary objective. In
addition to these a number of exploratory objectives will be investigated with blood
sampling.